The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

Completed

Conditions studied: Neoplasms, Cancer

In brief

GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malignancies, that will occur within one year of the first study blood draw.

Key facts

Study ID
NCT03085888
Run by
GRAIL, Inc.
People needed
99481
Starts
2017-02-28
Expected to finish
2024-04-01
Last updated by the study team
2024-09-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.